RecruitingNCT07059377
Semaglutide and support to stop smoking with type 2 diabetes
About this title
Read the official source — NCT07059377Medication studyAges 18+CanadaAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
What will I do during this study?
You are assigned to combination nicotine-replacement therapy alone or with semaglutide for up to six months. In the semaglutide group, the registry describes a weekly injection starting at 0.25 mg for four weeks, then increasing to 0.5 mg weekly.
- Listed locations
- OttawaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Participation duration
- Treatment can continue for up to 6 months; semaglutide is injected weekly.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 13, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Ottawa Heart Institute Research Corporation
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT07059377
- Official title
Show the full official title
Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Ottawa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Ottawa Heart Institute Research Corporation, a research institute.
Does this study involve medication?
Yes. The study involves medication, including Semaglutide and Nicotine replacement.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
